Vaginal Microbiota Transplantation: The Next Frontier

Citations of this article
Mendeley users who have this article in their library.
Get full text


The success of fecal microbiota transplantation (FMT) as a treatment for Clostrioides difficile infection (CDI) has stirred excitement about the potential for microbiota transplantation as a therapy for a wide range of diseases and conditions. In this article, we discuss vaginal microbiota transplantation (VMT) as “the next frontier” in microbiota transplantation and identify the medical, regulatory, and ethical challenges related to this nascent field. We further discuss what we anticipate will be the first context for testing VMT in clinical trials, prevention of the recurrence of a condition referred to as bacterial vaginosis (BV). We also compare clinical aspects of VMT with FMT and comment on how VMT may be similar to or different from FMT in ways that may affect research design and regulatory decisions.




DeLong, K., Zulfiqar, F., Hoffmann, D. E., Tarzian, A. J., & Ensign, L. M. (2019). Vaginal Microbiota Transplantation: The Next Frontier. Journal of Law, Medicine and Ethics, 47(4), 555–567.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free